• Blogroll

  • Blogpennystocks Book Store
  • Go Haceem!
  • IndoDONKEY

Cord Blood America (Public, OTC: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children.  The company’s mission is to be the most respected stem cell preservation company in the industry.  Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders.

For an initial fee of approx. $1,950 and an annual storage fee of approx. $125 for each year thereafter, the company provides the following services to each customer:

1. Collection
2. Full-Time Physician and Customer Support
3. Transportation
4. Comprehensive Testing
5. Cord Blood Preservation

Currently, all of Co.’s cord blood units are tested, processed and stored at Bergen Community Regional Blood Center in Paramus, NJ.

The stem cells are believed to play a key role in fighting disease as we move forward through this century.  Scientists are confident that stem cells will launch a new era in medicine, perhaps even curing some of our most current intractable diseases.  The umbilical cord which, at birth, traditionally has been thrown away, contains a rich store of stem cells.  Cord Blood America, Inc., through its wholly owned subsidiaries, CorCell Companies Inc., and Cord Partners, Inc., markets a service to preserve and store the umbilical cord blood in a patented process for future use exclusively by the donating family.  The collection takes less than five minutes, is painless, easy and non-invasive.  Cryogenically preserved umbilical cord stem cells have already been used to treat 75 major diseases, including leukemia, severe anemia, metabolic blood disorders and immune deficiencies.  This list is guaranteed to grow as medical research learns more about the incredible healing power of stem cells.

You cannot give birth to the same child twice.  That is why marketing, and education, is such an important factor in this sector.  Cord Blood America has assembled an experienced marketing team second to none in the industry.  They have nurtured deep relationships with healthcare insurance providers in key cities to drive the message to the parents when the insurance company is notified of that parent’s pregnancy.

Last month, Cord Blood America did a press release on how umbilical cord blood stem cells are being used in experimental effort to treat type 1 diabetes. Type 1 diabetes occurs when the body’s immune system cells attack the insulin-producing cells in the pancreas. This means the cells don’t produce enough insulin, and the lost insulin has to be replaced through injections for the patient to survive. The scientists involved in the experiment said the treatment could potentially be useful in other autoimmune diseases, such as lupus and rheumatoid arthritis.

A couple of hours later, another press release came out saying that the experiment was successful. said that stem cells from cord blood have been used to reeducate the immune system T cells of people with type 1 diabetes so their pancreas started producing again, lowering the amount of insulin they needed to inject.

The stock has not moved much the past 6 months.  In fact, it was slowly decreasing from $0.14 to $0.04 now.  If you want to invest, might as well do it for a long-term.  Click on the image to view the larger version.

Quote of the Day:
Behind every great fortune, there is a crime. – Honore de Balzac

I was doing my research the other day when I found this article below on transworldnews.com.  It talks about four penny stocks that might be worth watching.

Purio Inc. (Public, PINK: PURO) closed at $0.11. Today announced that it has accepted an invitation to meet with high ranking government officials from a region of West Africa to formally present its water/wastewater technology.

Participating in the meeting, scheduled for Saturday, November 22, will be The United Nations Development Program (UNDP), a number of financial institutions including United Bank of Africa, and a delegation of government dignitaries including The Minister of Presidential and Public Affairs. A private meeting between Purio Executives and the Minister is planned following the main event to discuss possible strategies regarding Purio’s involvement in the country’s development plans.

What They Do: Purio owns proprietary water clarification technology suitable to a broad number of applications including the clarification of surface water, industrial process water and sewage. Purio intends to apply its technology initially to industrial and commercial applications to reclaim water and reduce the need for fresh water in such applications. Purio further intends to use its proprietary technology to produce potable water for commercial and residential use. Purio will commercialize its technology via a number of channels, namely licensing strategic partners to build and sell &/or operate units outside of North America, outright sale of their second generation (patent pending) units to end users and will build, own and operate on a fee for service basis their larger permanent installation units in North America.

Perf Go Green Holdings (Public, PINK: PGOG) closed at $0.52. Today announced a distribution partnership with United Hardware Distributing Company. A full-line wholesale hardware distributor, United services more than 1,200 retail stores in 18 states and had sales of more than $170 million in 2007.

United Hardware Distributing Company, which has developed a dominant presence in the upper-Midwest, provides a wide range of products, retail programs, and support services to independent retailers. Headquartered in Plymouth, Minnesota, the company is 100% owned by its member-dealers, located in 18 states. United services its members from a 400,000 square foot distribution center located in Milbank, South Dakota. The distribution center stocks a complete merchandise assortment of more than 55,000 items.

What They Do: Perf Go Green Holdings is engaged in the creation and global marketing of 100% eco-friendly, non-toxic, food-contact-compliant, biodegradable plastic products. All Perf Go Green products are made from recycled plastics and completely break down in landfill within two years, leaving no toxic or visible residue, as compared to other plastics that take hundreds of years. Perf Go Green’s corporate name reflects its “Go Green” mission to develop, market and distribute biodegradable plastic products as a practical and viable solution to eliminating plastic waste from the world environment.

Deep Down (Public, OTC: DPDW) closed at $0.38. Today announced unaudited results for the three months and nine months ended September 30, 2008.

Revenue for the three months ended September 30, 2008 increased $6.8 million to $11.7 million, a 140% increase over the same three-month period in 2007. The increase in revenue included $8.5 million from the acquisitions of Mako and Flotation, while our historical service lines had an aggregate reduction in revenue of $1.7 million. The reduction in revenue in historical service lines, compared to the same three-month period in 2007, was impacted by two major engineering and product development projects which were completed prior to the third quarter of 2008. These projects had very low margins, and as such, were discontinued during the third quarter of 2008. The remaining reduction of revenues was a result of customers’ delaying many of their major projects due to the softening of the world oil price and the impact it had on anticipated cash flow of our customers.

Gross profit increased by $4.0 million to $5.3 million for the three months ended September 30, 2008 as compared to the same period last year. Gross margins for the same period improved from 25.8% to 45.5%. The inclusion of Mako and Flotation for the three months ended September 2008 increased the gross profit by $4.8 million while our historical service lines had an aggregate decrease of $0.8 million due to a reduction in revenue for this period as compared to the same period a year ago.

What They Do: Deep Down, Inc. provides products and services to the offshore energy industry to support deepwater exploration, development, and production of oil and gas, and other maritime operations worldwide. The company provides various project engineering and management services, including the design, installation, and retrieval of subsea equipment and systems; connection and termination operations; and commissioning. It also offers installation, retrieval, storage, and management services.

Aethlon Medical (Public, OTC: AEMD) closed at $0.28. Today announced that its Chairman and CEO, James A. Joyce has issued the following letter to shareholders:

To our Shareholders,

In my September shareholder letter, I referenced that our organization was heading into a pivotal month as we anticipated initial Hepatitis-C (HCV) treatment results from a safety study being conducted at the Fortis Hospital. The Fortis study allowed us the opportunity to enroll and test four HCV patients who each received a series of three, 4-hour Hemopurifier® treatments every other day during the course of five days. When considering the rapid replication of HCV combined with the disease being well established in each patient, we did not have tremendous clinical benefit expectations based on a short-term treatment schedule not optimized to reduce viral load. Much to our surprise, significant viral load reductions were observed in the first three patients. Patient #1 had a 95% reduction in viral load when tested three days post treatment and 89% reduction seven days post treatment. Patient #2 had an 85% reduction of viral load three days post treatment and 50% reduction seven days post treatment. Patient #3 had a 60% reduction of viral load three days post treatment and 83% reduction seven days post treatment. Initial data for the fourth patient has now been received for analysis and will be published in a formal clinical study report.

What They Do: Aethlon Medical, Inc. engages in the research and development of a medical device known as the Hemopurifier that removes harmful substances from the blood.

Click here to read more.

Quote of the Day:
For the final exam, I would take an internet company and say, ‘How much is this worth?’ And anybody that gave me an answer I would flunk. – Warren Buffett

Chemokine Therapeutics (Public, PINK: CHKT) is a product-focused biotechnology company that develops drugs that harness the therapeutic potential of stem cells through chemokine pathways.

Chemokines are a new class of cytokines, proteins which signal biological responses from stem cells that play a critical role in the growth, differentiation, and also maturation of cells necessary for fighting infection, as well as tissue repair and regeneration.

Stem cells are the master primitive cells that give rise to all of the cells and organs in the body. Chemokines are one of the major mediators of stem cell activity including stem cell growth, differentiation and maturation.

Being the leader in research in this field, the company currently has five products with two lead product candidates in clinical trials; CTCE-0214, for enhancing the immune system, and CTCE-9908, to prevent the spread of cancer and its continued growth.

Their main goal is to identify and develop multiple drug candidates for the treatment of cancer, blood disorders, cardiovascular and infectious disease.

Their recent press release states they had successfully reduced primary tumor growth in preclinical models of breast cancer with the treatment of the company’s CHCR4 antagonist and CTCE-9908.

In one study the investigators showed that mice treated with CTCE-9908 had statistically significant reduction of the primary tumor size compared to the control mice over time. At the 5-week and 6-week time points the mice treated with CTCE-9908 had an 86% decrease and 80% decrease in primary tumor growth compared to the control mice, respectively. In a second study, treatment with CTCE-9908 also demonstrated a statistically significant reduction in the rate of metastasis compared to the control group. At the 5-week and 6-week time points, the mice treated with CTCE-9908 had an 89% reduction and 95% reduction in metastatic tumor burden compared to the control mice, respectively.

Isn’t it exciting? Of course, at this moment they’re still far from their goal of creating a super drug that cures cancer. But it’s still pretty encouraging to see their recent experiment has turned out to be a tremendous success. For only 7 cents/share, this stock is definitely a bargain!

Quote of the Day:
My favorite time frame for holding a stock is forever. – Warren Buffett

Xenomics, Inc. (Symbol: XNOM) is the developer of next-generation molecular diagnostics products that address important health problems around the world. They are focusing on the development of DNA-based tests using Transrenal DNA or Tr-DNA.

Tr-DNAs are fragments of DNA derived from dying cells inside the body compartment. The intact DNA is fragmented in these dying cells, and then appears in the bloodstream. These fragments have been shown to cross the kidney barrier and can be detected in urine. Xenomics’ technology uses safe and simple urine collection to be applied to a broad range of testing, such as tumor detection, tissue transplants, infectious disease, even bio-terrorism.

Even though their stock performance in the past 3 months (see above) does not really look enticing, judging from the technology that they are currently developing – this stock can potentially be a good long-term investment. Let me give you a little bit of summary of their technology:

A particularly important feature of Tr-DNA diagnostic technology is that it is a true platform technology. This means that a single laboratory testing procedure designed to detect specific DNA biomarkers can be used to detect many forms of infectious diseases, cancer, transplanted cells and organs, or even prenatal detection of genetic markers of a fetus.

Tr-DNA tests are based upon a simple proprietary method of DNA isolation, followed by detection of DNA fragments bearing specific genetic markers. The detection methods and techniques are already well known and proven in molecular diagnostics laboratories where they are used to detect DNA in blood and a wide variety of specimens. Now these techniques are readily applied to the detection of Tr-DNA markers isolated from urine specimens. Thus, Tr-DNA technology may be applied to detecting and monitoring an extremely broad spectrum of medical conditions.

Additional advantages include:

• The kidney acts as a filter and presents purified Tr-DNA in the urine and, therefore, simplifies the sample preparation and DNA isolation steps currently required in the laboratory by other testing methods.
• The collection procedure is non-invasive and, therefore:
• Does not require the involvement of trained medical staff, and
• Easily supports repeated tests when conditions require and results in no discomfort for the patient.
• The Xenomics technology utilizes existing analytical equipment readily available in diagnostic laboratories through the world. Any new capital spending would be limited.
• Tr-DNA is stable at room temperature for extended periods. DNA in blood and many other traditional samples are not.
• Test processing can often be easily automated.
• Although many clinical Tr-DNA tests are performed using only a few drops of urine, it is readily possible to isolate these markers from larger volumes and thus increase the sensitivity of the test. This cannot be done easily using blood or tissue specimens.
• In many instances, blood or sputum for detection of infectious diseases cannot be easily obtained from many patients such as small children or the elderly. Urine specimens are not often a problem.
• Blood and other bodily fluids are highly infectious by nature, urine is not.

So…What do you think?

Source: xenomics.com

Quote of the Day:
Money may be the husk of many things but not the kernel. It brings you food, but not appetite; medicine, but not health; acquaintance, but not friends; servants, but not loyalty; days of joy, but not peace or happiness. – Henrik Ibsen

Biotech Holdings Ltd. is an integrated pharmaceutical company based in Vancouver, Canada, engaged in research, development, manufacture and marketing of pharmaceutical products.

The focus of the Company is the manufacturing and international marketing of SucanonTM, a new drug for the treatment of Type II Diabetes. Also known as Glucanin. The Company’s focus remains the development and distribution of Sucanon, particularly in Mexico and Latin America. During the fiscal year ended March 31, 2005, Biotech Holdings Ltd. began the manufacture of Sucanon.

In December 2004, the Company began shipping its Type II Diabetes drug Sucanon to Mexican retailers. On March 3, 2005, the Company announced that there was an expansion in the number of drugstore chains and other retail outlets carrying Sucanon in Mexico. Biotech Holdings Ltd. owns 75% of Smith Rothe Pharmaceutical Inc. (Smith Rothe). Smith Rothe holds the marketing rights for the Company’s Type II Diabetes drug in countries other than Asian Countries.

Following are a few of their investment highlights:

• Sucanon is one of only three drugs approved anywhere in the world, belonging to a new category of drugs called “insulin sensitizers”.
• Sucanon has received regulatory approval in Mexico. Mexico is the eighth largest pharmaceutical market and one of the largest diabetic markets in the world. Complications of diabetes is Mexico’s leading cause of death.
• Sales of the drug began in Mexico in early 2005. Sucanon is now sold in more than 600 stores nationally in Mexico including outlets of at least six drugstore chains.
• Sucanon has been approved in Peru and sales are planned to begin later this year. Preliminary distribution agreements for Sucanon have been negotiated in other Latin American countries.
• Internet sales of Sucanon are also planned.

The current trading price is very low, which is merely $0.05/share. It’s been fluctuating so much starting January 2006 and slowly declining – even though it once went up as high as $0.11/share in August, it quickly dropped again and finally settled at $0.05/share. I personally like the product that they currently develop; however, looking at their stock perfomance in the past 9 months, I have become very hesitant whether I should invest in this stock or not. Hmm..I’ll probably put this one under my stock-watch list and see what is going to happen in the next few months. Yup, we’ll see…….

Source: http://finance.google.com

Quote of the Day:
Each time, it’s a nice little company, nice people, modestly successful. Then you bring in the VC money – it’s like putting jet engines on a VW. They expect that, within a year and a half, they will get back ten times their money. – Dennis Faust

Next Page →

• Search



• Categories

  • Apparel/Accessories
  • Biotechnology & Drugs
  • Business Services
  • Chemical Manufacturing
  • Communication Services
  • Communications Equipment
  • Computer Hardware
  • Computer Services
  • Electronic Instr. & Controls
  • Energy
  • Medical Equipment & Supplies
  • Nanotechnology
  • Oil & Gas Operations
  • Other
  • Recreational Products
  • Retail
  • Security Systems & Services
  • Software & Programming

• Archives

  • February 2012
  • January 2012
  • June 2009
  • December 2008
  • November 2008
  • December 2007
  • October 2007
  • August 2007
  • July 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • December 2006
  • November 2006
  • October 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • February 2006
  • December 2005
  • November 2005
  • May 2005
  • April 2005
  • March 2005
  • February 2005
  • January 2005
  • December 2004
  • November 2004
  • October 2004
  • September 2004